• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Prescribing patterns and drug-related problems (DRPs) in transfusion-dependent paediatric thalassemia patients: A prospective interventional study from a tertiary care hospital in India.输血依赖型小儿地中海贫血患者的用药模式及药物相关问题:来自印度一家三级护理医院的前瞻性干预研究。
Int J Pediatr Adolesc Med. 2021 Mar;8(1):35-38. doi: 10.1016/j.ijpam.2020.01.001. Epub 2020 Jan 7.
2
Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia.甲磺酸去铁胺用于治疗依赖输血的地中海贫血患者的输血性铁过载。
Cochrane Database Syst Rev. 2013 Aug 21;2013(8):CD004450. doi: 10.1002/14651858.CD004450.pub3.
3
Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial.去铁酮与地拉罗司治疗依赖输血的血红蛋白病儿科患者的疗效和安全性评估(DEEP-2):一项多中心、随机、开放标签、非劣效性3期试验。
Lancet Haematol. 2020 Jun;7(6):e469-e478. doi: 10.1016/S2352-3026(20)30100-9.
4
Polypharmacy and medication regimen complexity in transfusion-dependent thalassaemia patients: a cross- sectional study.输血依赖型地中海贫血患者的多种药物治疗和药物治疗方案复杂性:一项横断面研究。
Int J Clin Pharm. 2024 Jun;46(3):736-744. doi: 10.1007/s11096-024-01716-y. Epub 2024 Mar 29.
5
Safety and efficacy of deferasirox in multitransfused Indian children with β-thalassaemia major.地拉罗司在多次输血的重度β地中海贫血印度儿童中的安全性和有效性。
Ann Trop Paediatr. 2011;31(1):47-51. doi: 10.1179/1465328110Y.0000000002.
6
Safety Profile of Oral Iron Chelator Deferiprone in Chinese Children with Transfusion-Dependent Thalassaemia.口服铁螯合剂去铁酮在中国依赖输血的地中海贫血儿童中的安全性概况
Curr Drug Saf. 2016;11(2):137-44. doi: 10.2174/1574886310666150930113957.
7
Deferasirox for managing iron overload in people with thalassaemia.地拉罗司用于治疗地中海贫血患者的铁过载。
Cochrane Database Syst Rev. 2012 Feb 15(2):CD007476. doi: 10.1002/14651858.CD007476.pub2.
8
Use of Iron Chelating Agents in Transfusion Dependent Thalassaemia Major Patients.铁螯合剂在重型输血依赖型地中海贫血患者中的应用
Mymensingh Med J. 2015 Oct;24(4):838-44.
9
Drug-related problems in geriatric rehabilitation patients after discharge - A prevalence analysis and clinical case scenario-based pilot study.老年康复患者出院后与药物相关的问题 - 基于患病率分析和临床病例情景的初步研究。
Res Social Adm Pharm. 2018 Jul;14(7):628-637. doi: 10.1016/j.sapharm.2017.07.009. Epub 2017 Jul 25.
10
Drug related problems identified by community pharmacists on hospital discharge prescriptions in New Zealand.新西兰社区药剂师在出院处方中发现的与药物相关的问题。
Int J Clin Pharm. 2014 Jun;36(3):498-502. doi: 10.1007/s11096-014-9935-8. Epub 2014 Apr 4.

引用本文的文献

1
Drug-related problems among transfusion-dependent thalassemia patients: A real-world evidence study.依赖输血的地中海贫血患者的药物相关问题:一项真实世界证据研究。
Front Pharmacol. 2023 Apr 20;14:1128887. doi: 10.3389/fphar.2023.1128887. eCollection 2023.

本文引用的文献

1
How I manage medical complications of β-thalassemia in adults.成人β-地中海贫血症的医学并发症管理方法。
Blood. 2018 Oct 25;132(17):1781-1791. doi: 10.1182/blood-2018-06-818187. Epub 2018 Sep 11.
2
Optimising management of deferasirox therapy for patients with transfusion-dependent thalassaemia and lower-risk myelodysplastic syndromes.优化依赖输血的地中海贫血和低危骨髓增生异常综合征患者的地拉罗司治疗管理。
Eur J Haematol. 2018 Sep;101(3):272-282. doi: 10.1111/ejh.13111. Epub 2018 Jul 27.
3
Efficacy of Deferasirox as an Oral Iron Chelator in Paediatric Thalassaemia Patients.地拉罗司作为口服铁螯合剂在小儿地中海贫血患者中的疗效
J Clin Diagn Res. 2017 Feb;11(2):FC01-FC03. doi: 10.7860/JCDR/2017/22650.9395. Epub 2017 Feb 1.
4
A Review on Iron Chelators in Treatment of Iron Overload Syndromes.铁螯合剂治疗铁过载综合征的综述
Int J Hematol Oncol Stem Cell Res. 2016 Oct 1;10(4):239-247.
5
Synergistic intracellular iron chelation combinations: mechanisms and conditions for optimizing iron mobilization.协同细胞内铁螯合组合:优化铁动员的机制和条件。
Br J Haematol. 2015 Sep;170(6):874-83. doi: 10.1111/bjh.13512. Epub 2015 Jun 1.
6
Preventing and treating infections in children with asplenia or hyposplenia.预防和治疗无脾或脾功能减退儿童的感染。
Paediatr Child Health. 2014 May;19(5):271-8.
7
Improved efficacy and tolerability of oral deferasirox by twice-daily dosing for patients with transfusion-dependent β-thalassemia.口服地拉罗司每日 2 次给药可提高依赖输血的β-地中海贫血患者的疗效和耐受性。
Pediatr Blood Cancer. 2011 Mar;56(3):420-4. doi: 10.1002/pbc.22826.
8
Alpha and beta thalassemia.α和β地中海贫血
Am Fam Physician. 2009 Aug 15;80(4):339-44.
9
The thalassemias and related disorders.地中海贫血及相关疾病
Proc (Bayl Univ Med Cent). 2007 Jan;20(1):27-31. doi: 10.1080/08998280.2007.11928230.
10
Focusing on the preventability of adverse drug reactions.关注药物不良反应的可预防性。
Hosp Pharm. 1992 Jun;27(6):538.

输血依赖型小儿地中海贫血患者的用药模式及药物相关问题:来自印度一家三级护理医院的前瞻性干预研究。

Prescribing patterns and drug-related problems (DRPs) in transfusion-dependent paediatric thalassemia patients: A prospective interventional study from a tertiary care hospital in India.

作者信息

Babu Tirin, Mathew Panachiyil George, Sebastian Juny, Dhati Ravi Mandyam

机构信息

Department of Pharmacy Practice, JSS College of Pharmacy, JSS Academy of Higher Education & Research, Mysuru, Karnataka, 570015, India.

Department of Paediatrics, JSS Medical College and Hospital, JSS Academy of Higher Education & Research, Mysuru, Karnataka, 570015, India.

出版信息

Int J Pediatr Adolesc Med. 2021 Mar;8(1):35-38. doi: 10.1016/j.ijpam.2020.01.001. Epub 2020 Jan 7.

DOI:10.1016/j.ijpam.2020.01.001
PMID:33718575
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7922838/
Abstract

BACKGROUND

Each year nearly 10,000 children with thalassaemia major are born in India, but among them, very few are optimally managed mainly in urban regions even though the Government of India has incorporated their care and treatment in the 12th Five-Year Plan. Data on prescribing patterns and drug-related problems (DRPs) in paediatric thalassaemia patients in India are limited.

METHODS

In this prospective interventional study, the medications prescribed were recorded after reviewing the treatment charts, thalassaemia register, thalassaemia card, nurses' notes, as well as discharge summaries. When DRPs and/or medication errors were identified, the same was discussed with the concerned health care professionals and suitable suggestions were made at the earliest.

RESULTS

Out of the enrolled 54 patients, only 94% (n = 51) of the patients received iron chelation therapy with deferasirox and/or deferiprone, Folic acid tablet was prescribed for 100% of the patients (n = 54). Five percent of patients (n = 3) had undergone splenectomy and was prescribed with amoxicillin prophylactically. There were a total of 16 DRPs and 15 medication errors were identified and suitable measurements were taken to solve these problems.

CONCLUSIONS

The prescribing patterns, DRPs and medication errors in transfusion-dependent paediatric thalassaemia patients were discussed in this study. Our study was effective in identifying and solving the DRPs and medication problems that occurred in thalassaemia patients.

摘要

背景

印度每年有近10000名重型地中海贫血患儿出生,但即便印度政府已将对他们的护理和治疗纳入第十二个五年计划,其中仍只有极少数在城市地区得到了最佳管理。关于印度小儿地中海贫血患者的处方模式和药物相关问题(DRP)的数据有限。

方法

在这项前瞻性干预研究中,通过查阅治疗图表、地中海贫血登记册、地中海贫血卡片、护士记录以及出院小结来记录所开的药物。当发现DRP和/或用药错误时,会与相关医护人员进行讨论,并尽早提出适当建议。

结果

在纳入研究的54名患者中,只有94%(n = 51)的患者接受了地拉罗司和/或去铁酮的铁螯合治疗,100%的患者(n = 54)都开了叶酸片。5%的患者(n = 3)接受了脾切除术,并预防性地开了阿莫西林。总共发现了16个DRP和15个用药错误,并采取了适当措施来解决这些问题。

结论

本研究讨论了输血依赖型小儿地中海贫血患者的处方模式、DRP和用药错误。我们的研究有效地识别并解决了地中海贫血患者中出现的DRP和用药问题。